Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities

Eur J Med Chem. 2012 Aug:54:764-70. doi: 10.1016/j.ejmech.2012.06.033. Epub 2012 Jun 29.

Abstract

With the introduction of bioisosteres of the guanidinium group together with scaffold hopping, 35 zanamivir analogs with C-4-modification were synthesized, and their inhibitory activities against both group-1 and group-2 neuraminidase (H5N1 and H3N2) were determined. Compound D26 exerts the most potency, with IC(50) values of 0.58 and 2.72 μM against N2 and N1, respectively. Further preliminary anti-avian influenza virus (AIV, H5N1) activities against infected MDCK cells were evaluated, and D5 exerts ∼58% protective against AIV infection, which was comparable to zanamivir (∼67%). In a rat pharmacokinetic study, compound D5 showed an increased plasma half-life (t(1/2)) compared to zanamivir following either intravenous or oral administration. This study may represent a new start point for the future development of improved anti-AIV agents.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiviral Agents / chemical synthesis
  • Antiviral Agents / chemistry
  • Antiviral Agents / pharmacokinetics
  • Antiviral Agents / pharmacology
  • Chemistry Techniques, Synthetic
  • Dogs
  • Enzyme Inhibitors / chemical synthesis
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacokinetics
  • Enzyme Inhibitors / pharmacology
  • Influenza A Virus, H3N2 Subtype / drug effects*
  • Influenza A Virus, H3N2 Subtype / enzymology*
  • Influenza A Virus, H5N1 Subtype / drug effects*
  • Influenza A Virus, H5N1 Subtype / enzymology*
  • Madin Darby Canine Kidney Cells
  • Male
  • Neuraminidase / antagonists & inhibitors*
  • Rats
  • Zanamivir / chemical synthesis*
  • Zanamivir / chemistry
  • Zanamivir / pharmacokinetics
  • Zanamivir / pharmacology*

Substances

  • Antiviral Agents
  • Enzyme Inhibitors
  • Neuraminidase
  • Zanamivir